Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 5/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.31 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.31 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.31 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2314601 | 1.00 | CMA1 (0.36) | CMA1SLC6A3ALKEGLN1MDM2 | |
| SCHEMBL2310720 | 0.93 | CMA1 (0.35) | CMA1EGLN1NR3C1NR3C2PGR | |
| SCHEMBL2310727 | 0.93 | CMA1 (0.35) | CMA1EGLN1NR3C1NR3C2PGR | |
| SCHEMBL2313900 | 0.90 | CMA1 (0.36) | CMA1SLC6A3ALKMDM2 | |
| SCHEMBL2313894 | 0.90 | CMA1 (0.36) | CMA1SLC6A3ALKMDM2 | |
| SCHEMBL2314485 | 0.90 | CMA1 (0.35) | CMA1EGLN1 | |
| SCHEMBL2308199 | 0.90 | CMA1 (0.35) | CMA1EGLN1 | |
| SCHEMBL2315320 | 0.89 | KDM4E (0.36) | MDM2NR3C1NR3C2PGR | |
| SCHEMBL2315326 | 0.89 | KDM4E (0.36) | MDM2NR3C1NR3C2PGR | |
| SCHEMBL2309175 | 0.86 | CMA1 (0.40) | CMA1EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150556-B2 | Benzimidazolone chymase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-06 | — | — | US | disclosed |
| EP-2152674-B1 | BENZIMIDAZOLONE CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2011-08-03 | — | — | EP | disclosed |
| US-20100240702-A1 | Benzimidazolone Chymase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240702-A1 | Benzimidazolone Chymase Inhibitors | CMA1, SERPINB1, CPA3 | CMA1 1/4885SLC6A3 4421/4885ALK 1338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.